Bioregulatory tripeptide targeting the pineal gland, researched for neuroprotection, cognitive preservation, and melatonin regulation.
Last Updated: May 2026
Pinealon is a synthetic tripeptide (Glu-Asp-Arg) from the Khavinson bioregulator family, researched for pineal-gland-targeted neuroprotection, cognitive preservation, and melatonin pathway regulation. It is one of the synthesized (rather than tissue-extracted) Khavinson compounds, with a defined three-amino-acid sequence. Pinealon is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.
Pinealon is a synthetic Glu-Asp-Arg tripeptide proposed to enter pineal-cell nuclei and modulate gene expression in pathways related to melatonin synthesis, antioxidant response, and neuroprotection. The Khavinson framework treats Pinealon as the tripeptide complement to the tetrapeptide Epithalon, with both targeting pineal tissue but through proposed-distinct sequence-specific gene-expression effects. Preclinical work has reported effects on oxidative stress response, neuronal apoptosis pathways, and cognitive performance markers in rodent models. Evidence level: Preclinical (rodent neuroprotection, oxidative stress); Khavinson-group human research; independent replication limited.
Preclinical rodent studies from the Khavinson group have reported neuroprotective effects against oxidative stress, improved cognitive performance markers in aging rodents, and effects on pineal gene expression related to melatonin synthesis. Human research has been conducted in Russian clinical contexts but is not characterized at FDA-grade Phase 2/3 standards. The most-cited mechanistic study (Khavinson et al., 2014) reported nuclear entry of fluorescently-labeled Pinealon and binding to specific DNA sequences in cultured cells. Evidence level: Preclinical (rodent and cell culture); Khavinson-group human research; FDA-grade Phase 2/3 not conducted.
Pinealon and Epithalon are the two Khavinson bioregulators specifically targeting pineal gland tissue — Pinealon is a tripeptide proposed for neuroprotection and melatonin pathway support, Epithalon is a tetrapeptide proposed for telomerase activation and broader aging effects. They are often used together in Khavinson-protocol research.
| Bioregulator | Structure | Target tissue | Primary research focus |
|---|---|---|---|
| Pinealon | Tripeptide (Glu-Asp-Arg) | Pineal / brain | Neuroprotection, cognition |
| Epithalon | Tetrapeptide (Ala-Glu-Asp-Gly) | Pineal | Telomerase, longevity |
| Cartalax | Tripeptide (Ala-Glu-Asp) | Cartilage | Joint, connective tissue |
| Cardiogen | Tetrapeptide (Ala-Glu-Asp-Arg) | Cardiac | Myocardial function |
Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The Khavinson bioregulator class as a whole has a favorable safety profile in available data, attributed to the short peptide length and proposed nuclear-entry mechanism that does not engage surface receptor cascades. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished at Western clinical standards.
Pinealon is not approved by the FDA, EMA, or any major Western regulator as of May 2026. It is used in Russian clinical and research contexts as part of Khavinson-framework protocols but does not have a defined Western regulatory pathway. The FDA's broader position on bioregulator peptides has been in flux during 2024–2026 — see FDA peptide regulation 2025–2026 timeline.
Pinealon's short tripeptide structure makes synthesis straightforward and broadly available across research-grade vendors, but identity and purity verification still matters — related Khavinson tripeptides can be mislabeled, and the small molecular weight (~419 Da) requires mass spectrometry confirmation to distinguish from other short peptides. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases Pinealon vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. The lab test table above this section shows the cross-shop dataset. Methodology in how we calculate trust scores.
Pinealon is proposed to act on pineal gland tissue through epigenetic gene-expression modulation, with preclinical research focused on neuroprotection, oxidative stress reduction, and cognitive performance markers. Effects in humans at Western Phase 2/3 standards are not characterized; the evidence base comes from the Khavinson research group and Russian clinical contexts.
Both target pineal gland tissue but have different sequences (Pinealon is a tripeptide Glu-Asp-Arg; Epithalon is a tetrapeptide Ala-Glu-Asp-Gly) and different proposed primary effects — Pinealon for neuroprotection and cognitive markers, Epithalon for telomerase activation and broader anti-aging effects. They are often used together in Khavinson-protocol research.
Pinealon is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.
No active FDA approval pathway exists for Pinealon as of May 2026. Bioregulator peptides are not currently being advanced through FDA clinical development by any pharmaceutical sponsor.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation (expected MW ~419 Da). COA interpretation in red flags in peptide certificates of analysis.
No. Pinealon is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Khavinson-protocol dosing varies by research context. Anyone considering use should consult a licensed physician.
This section is for educational and informational purposes only and does not constitute medical advice. Pinealon is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.